Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis

References

• Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322. doi:10.1016/j.clim.2019.108322.
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40(1):74–79. doi:10.3899/jrheum.120583.
   PubMed Web of Science ®Google Scholar
• Hawkins MJ, Dick AD, Lee RJW, et al. Managing juvenile idiopathic arthritis–associated uveitis. Surv Ophthalmol. 2016;61(2):197–210. doi:10.1016/j.survophthal.2015.10.005.
   PubMed Web of Science ®Google Scholar
• Haasnoot AJW, van Tent-hoeve M, Wulffraat NM. Erythrocyte sedimentation rate as baseline predictor for the development of uveitis in children with juvenile idiopathic arthritis. Am J Ophthalmol. 2015;159(2):372–377. doi:10.1016/j.ajo.2014.11.007.
   PubMed Web of Science ®Google Scholar
• Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol. 2006;244(3):281–290. doi:10.1007/s00417-005-0087-3.
   PubMed Web of Science ®Google Scholar
• Garcia-De-Vicuna C, Diaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:560632. doi:10.1155/2013/560632.
   PubMed Web of Science ®Google Scholar
• Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014;12(1):13. doi:10.1186/1546-0096-12-13.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007;17(5):743–748. doi:10.1177/112067210701700509.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert Panel Recommendations for the Use of Anti–Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology. 2014;121(3):785–796. doi:10.1016/j.ophtha.2013.09.048.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39(6):1294‐5. doi:10.3899/jrheum.120010.
   PubMed Web of Science ®Google Scholar
• Adan A, Mesquida M, Llorenc V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627–2632. doi:10.1007/s00417-013-2436-y.
   PubMed Web of Science ®Google Scholar
• Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22(2):155–157. doi:10.3109/09273948.2013.866254.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135–41. doi:10.1016/S2665-9913(20)30008-4.
   PubMedGoogle Scholar
• Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: multicenter Study of 25 Patients. Am J Ophthalmol. 2019;200:85–94. doi:10.1016/j.ajo.2018.12.019.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior Uveitis. Ophthalmology. 1985;92(4):467–471. doi:10.1016/S0161-6420(85)34001-0.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34(9):1158–1163. doi:10.1002/art.1780340912.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Robbioni P, Massa M, Viola S, Albani S, Martini A. Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis.. Clin Exp Rheumatol. 1992;10:493–498.
   PubMed Web of Science ®Google Scholar
• Wehrens EJ, Vastert SJ, Mijnheer G, et al. Brief Report: anti-Tumor Necrosis Factor α Targets Protein Kinase B/c-Akt-Induced Resistance of Effector Cells to Suppression in Juvenile Idiopathic Arthritis. Arthritis Rheum. 2013;65(12):3279–3284. doi:10.1002/art.38132.
   PubMedGoogle Scholar
• Woo P, Humphries SE. IL-6 polymorphisms: A useful genetic tool for inflammation research? J Clin Invest. 2013;123(4):1413–1414. doi:10.1172/JCI67221.
   PubMed Web of Science ®Google Scholar
• Giancane G, Alongi A, Ravelli A. Update on the pathogenesis and treatment of juvenile idiopathic arthritis. Curr Opin Rheumatol. 2017;29(5):523–529. doi:10.1097/BOR.0000000000000417.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2013;65(12):3279–3284] has been updated. OK?</chg>. doi:10.1136/annrheumdis-2014-205351.
   Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–2395. doi:10.1056/NEJMoa1112802.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–997. doi:10.1016/S0140-6736(08)60453-5.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317–328. doi:10.1056/NEJMoa1613849.
   Google Scholar
• Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43(12):2183‐8. doi:10.3899/jrheum.160231.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Santos-Gómez M, Calvo I. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol. 2017;69(3):668–675. doi:10.1002/art.39940.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study).. Ann Rheum Dis. 2014;73(1):69–74. doi:10.1136/annrheumdis-2013-203523.
   PubMed Web of Science ®Google Scholar
• Quesada-Masachs E, Caballero CM. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis–associated Uveitis. J Rheumatol. 2017;44(2):260–261. doi:10.3899/jrheum.160908.
   PubMed Web of Science ®Google Scholar